Cardiovascular research · 2026
Immune regulation following allogeneic iPSC-derived cardiomyocyte transplantation in non-human primates.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chino Shuji, Ichimura Hajime, Tohyama Shugo, Kobayashi Hideki, Shiina Takashi, Sakai Hiroki, Fukuda Keiichi, Tomita Takuro, Yamada Mitsuhiko, Tateishi Ayako, Ohya Maki, Kobayashi Mikiko, Kanno Hiroyuki, Ishigaki Hirohito, Agata Masahiro, Takahashi Hidekazu, Zhao Jian, Yang Xiao, Omar Zouhour G, Caruso Ada, Tanaka Yuki, Shiba Naoko, Wada Yuko, Seto Tatsuichiro, Chong James J H, Kadota Shin, Shiba Yuji
Аннотация
AIMS: This study explores the efficacy of immunosuppressive regimens commonly used in heart transplantation for promoting the survival of allogeneic induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) grafts in non-human primates, specifically cynomolgus monkeys.
METHODS AND RESULTS: By combining methylprednisolone (MPL), calcineurin inhibitors (CNIs), and mycophenolate mofetil (MMF), we ensured adequate graft survival without acute rejection. Histological analysis showed iPSC-CM survival, vascularization, and minimal immune rejection, despite immaturity. Reducing the immunosuppressive regimen by omitting MPL and using only CNIs and MMF resulted in graft rejection, underscoring the need for all three immunosuppressants. Genetically modified hypo-immune iPSC-CMs had poor engraftment due to increased apoptosis, unrelated to immune rejection. Additionally, abatacept in combination with tacrolimus allowed MPL discontinuation without rejection, whereas amiodarone and ivabradine effectively prevented the occurrence of post-transplant ventricular arrhythmias and reduced the incidence of sudden cardiac death.
CONCLUSION: These findings highlight the importance of optimized immunosuppressant regimens for iPSC-CM graft survival and the potential improvements in clinical outcomes in patients with severe heart failure.
METHODS AND RESULTS: By combining methylprednisolone (MPL), calcineurin inhibitors (CNIs), and mycophenolate mofetil (MMF), we ensured adequate graft survival without acute rejection. Histological analysis showed iPSC-CM survival, vascularization, and minimal immune rejection, despite immaturity. Reducing the immunosuppressive regimen by omitting MPL and using only CNIs and MMF resulted in graft rejection, underscoring the need for all three immunosuppressants. Genetically modified hypo-immune iPSC-CMs had poor engraftment due to increased apoptosis, unrelated to immune rejection. Additionally, abatacept in combination with tacrolimus allowed MPL discontinuation without rejection, whereas amiodarone and ivabradine effectively prevented the occurrence of post-transplant ventricular arrhythmias and reduced the incidence of sudden cardiac death.
CONCLUSION: These findings highlight the importance of optimized immunosuppressant regimens for iPSC-CM graft survival and the potential improvements in clinical outcomes in patients with severe heart failure.